avacincaptad pegol
avacincaptad pegol: developed by 1 company · 2 clinical trials tracked.
avacincaptad pegol evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
How could avacincaptad pegol → ISEE affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| IVERIC bio, Inc. (ISEE) | Phase 3 |
Clinical Trials (2)
A Phase 3 Multicenter, Randomized, Double Masked, Sham- Controlled Clinical Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura (Complement C5 Inhibitor) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Primary endpoint: The Mean Rate of Growth (Slope) Estimated Based on GA Area Measured by Autofluorescence (FAF) at 3 Time Points: Baseline, Month 6, and Month 12
A Phase 2/3 Randomized, Double-Masked, Controlled Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura™ (Anti-C5 Aptamer) in Patients With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Primary endpoint: Change From Baseline in Geographic Atrophy as Measured by Fundus Autofluorescence
Frequently asked questions
Who is developing avacincaptad pegol?
avacincaptad pegol is being developed by IVERIC bio, Inc..
How many clinical trials involve avacincaptad pegol?
BioSniper tracks 2 clinical trials involving avacincaptad pegol.